American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with …
D Farge, H Bounameaux, B Brenner… - The Lancet …, 2016 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at an increased risk of developing VTE and are more likely to …
cancer. These patients are at an increased risk of developing VTE and are more likely to …
Heparin: past, present, and future
EI Oduah, RJ Linhardt, ST Sharfstein - Pharmaceuticals, 2016 - mdpi.com
Heparin, the most widely used anticoagulant drug in the world today, remains an animal-
derived product with the attendant risks of adulteration and contamination. A contamination …
derived product with the attendant risks of adulteration and contamination. A contamination …
The anticoagulant and nonanticoagulant properties of heparin
DMH Beurskens, JP Huckriede… - Thrombosis and …, 2020 - thieme-connect.com
Heparins represent one of the most frequently used pharmacotherapeutics. Discovered
around 1926, routine clinical anticoagulant use of heparin was initiated only after the …
around 1926, routine clinical anticoagulant use of heparin was initiated only after the …
Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells
Ovarian cancer has a poor overall survival that is partly caused by resistance to drugs such
as cisplatin. Resistance can be acquired as a result of changes to the tumour or due to …
as cisplatin. Resistance can be acquired as a result of changes to the tumour or due to …
Role of heparanase in tumor progression: Molecular aspects and therapeutic options
Heparanase (HPSE) is an endoglycosidase that catalyses the cutting of the side chains of
heparan-sulphate proteoglycans (HS), thus determining the remodelling of the extracellular …
heparan-sulphate proteoglycans (HS), thus determining the remodelling of the extracellular …
The role of coagulome in the tumor immune microenvironment
The rising incidence and persistent thrombosis in multiple cancers including those that are
immunosuppressive highlight the need for understanding the tumor coagulome system and …
immunosuppressive highlight the need for understanding the tumor coagulome system and …
Targeting heparanase in cancer: inhibition by synthetic, chemically modified, and natural compounds
CD Mohan, S Hari, HD Preetham, S Rangappa… - Iscience, 2019 - cell.com
Heparanase is an endoglycosidase involved in remodeling the extracellular matrix and
thereby in regulating multiple cellular processes and biological activities. It cleaves heparan …
thereby in regulating multiple cellular processes and biological activities. It cleaves heparan …
[HTML][HTML] Old and new applications of non-anticoagulant heparin
G Cassinelli, A Naggi - International Journal of Cardiology, 2016 - Elsevier
The aim of this chapter is to provide an overview of non-anticoagulant effects of heparins
and their potential use in new therapeutic applications. Heparin and heparin derivatives …
and their potential use in new therapeutic applications. Heparin and heparin derivatives …
Anticoagulation for the prevention of arterial thrombosis in ambulatory cancer patients: systematic review and meta-analysis
Background The risk of arterial thrombotic events (ATEs) is high among patients on systemic
anticancer therapies. Despite the efficacy of anticoagulants in the prevention of cancer …
anticancer therapies. Despite the efficacy of anticoagulants in the prevention of cancer …